1. history of respiratory and cardiovascular diseases, hematologic disease (e.g., cryoglobulinemia, lymphoma), renal disease, dermatologic disease (e.g., lichen planus, porphyria cutanea tarda). 2. autoimmune diseases or clinically serious cardiac, pulmonary, gastrointestinal, hepatic, renal or neurologic disease, which in the opinion of the investigator will compromise ability to participate in the study. 3. pregnancy and breast-feeding. 4. prior or current systemic cancer chemotherapy. 5. investigational agents and immunomodulators (cyclosporine, hematological growth factors, systemic corticosteroids, interleukins or interferons) within 90 days prior to study entry. 6. anaphylaxis or allergy to vaccine components. 7. active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. 8. any other serious diseases other than covid-19 infection including current or recent (within 5 years) cancers. 9. subjects who are immunocompromised or immunosuppressed due to disease or medications. 10. women who are lactating.

1. history of respiratory and cardiovascular diseases, hematologic disease (e.g., cryoglobulinemia, lymphoma), renal disease, dermatologic disease (e.g., lichen planus, porphyria cutanea tarda). 2. autoimmune diseases or clinically serious cardiac, pulmonary, gastrointestinal, hepatic, renal or neurologic disease, which in the opinion of the investigator will compromise ability to participate in the study. 3. pregnancy and breast-feeding. 4. prior or current systemic cancer chemotherapy. 5. investigational agents and immunomodulators (cyclosporine, hematological growth factors, systemic corticosteroids, interleukins or interferons) within 90 days prior to study entry. 6. anaphylaxis or allergy to vaccine components. 7. active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. 8. any other serious diseases other than covid-19 infection including current or recent (within 5 years) cancers. 9. subjects who are immunocompromised or immunosuppressed due to disease or medications. 10. women who are lactating.

history of respiratory and cardiovascular diseases, hematologic disease (e.g., cryoglobulinemia, lymphoma), renal disease, dermatologic disease (e.g., lichen planus, porphyria cutanea tarda). autoimmune diseases or clinically serious cardiac, pulmonary, gastrointestinal, hepatic, renal or neurologic disease, which in the opinion of the investigator will compromise ability to participate in the study. pregnancy and breast-feeding. prior or current systemic cancer chemotherapy. investigational agents and immunomodulators (cyclosporine, hematological growth factors, systemic corticosteroids, interleukins or interferons) within 90 days prior to study entry. anaphylaxis or allergy to vaccine components. active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. any other serious diseases other than covid-19 infection including current or recent (within 5 years) cancers. subjects who are immunocompromised or immunosuppressed due to disease or medications. women who are lactating.

history of respiratory and cardiovascular diseases, hematologic disease (e.g., cryoglobulinemia, lymphoma), renal disease, dermatologic disease (e.g., lichen planus, porphyria cutanea tarda). autoimmune diseases or clinically serious cardiac, pulmonary, gastrointestinal, hepatic, renal or neurologic disease, which in the opinion of the investigator will compromise ability to participate in the study. pregnancy and breast-feeding. prior or current systemic cancer chemotherapy. investigational agents and immunomodulators (cyclosporine, hematological growth factors, systemic corticosteroids, interleukins or interferons) within 90 days prior to study entry. anaphylaxis or allergy to vaccine components. active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. any other serious diseases other than covid-19 infection including current or recent (within 5 years) cancers. subjects who are immunocompromised or immunosuppressed due to disease or medications. women who are lactating.

1. history of respiratory and cardiovascular diseases, hematologic disease (e.g., cryoglobulinemia, lymphoma), renal disease, dermatologic disease (e.g., lichen planus, porphyria cutanea tarda). 2. autoimmune diseases or clinically serious cardiac, pulmonary, gastrointestinal, hepatic, renal or neurologic disease, which in the opinion of the investigator will compromise ability to participate in the study. 3. pregnancy and breast-feeding. 4. prior or current systemic cancer chemotherapy. 5. investigational agents and immunomodulators (cyclosporine, hematological growth factors, systemic corticosteroids, interleukins or interferons) within 90 days prior to study entry. 6. anaphylaxis or allergy to vaccine components. 7. active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. 8. any other serious diseases other than covid-19 infection including current or recent (within 5 years) cancers. 9. subjects who are immunocompromised or immunosuppressed due to disease or medications. 10. women who are lactating.

1. history of respiratory and cardiovascular diseases, hematologic disease (e.g., cryoglobulinemia, lymphoma), renal disease, dermatologic disease (e.g., lichen planus, porphyria cutanea tarda). 2. autoimmune diseases or clinically serious cardiac, pulmonary, gastrointestinal, hepatic, renal or neurologic disease, which in the opinion of the investigator will compromise ability to participate in the study. 3. pregnancy and breast-feeding. 4. prior or current systemic cancer chemotherapy. 5. investigational agents and immunomodulators (cyclosporine, hematological growth factors, systemic corticosteroids, interleukins or interferons) within 90 days prior to study entry. 6. anaphylaxis or allergy to vaccine components. 7. active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. 8. any other serious diseases other than covid-19 infection including current or recent (within 5 years) cancers. 9. subjects who are immunocompromised or immunosuppressed due to disease or medications. 10. women who are lactating.